Hoth Therapeutics Adopts Lantern Pharma's AI Platform for Drug Development
Hoth Therapeutics is leveraging Lantern Pharma's PredictBBB.ai platform to enhance its drug development processes, announced in a press release. The AI tool, part of Lantern's RADR platform, boasts a 94% accuracy rate in predicting blood-brain barrier permeability, a critical factor in drug candidate success.
By adopting this technology, Hoth aims to streamline candidate selection, reduce development risks, and accelerate timelines for therapeutic discovery. The integration of PredictBBB.ai is expected to provide AI-powered insights that increase precision and reduce uncertainty in drug development, potentially leading to faster regulatory pathways and higher value inflection points for Hoth's pipeline.
Lantern Pharma's CEO, Panna Sharma, expressed enthusiasm for the early adoption of their platform by innovators like Hoth Therapeutics, highlighting the potential of PredictBBB.ai to be a game-changer in central nervous system drug development.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Atlas Bio raises $12.5 million for virtual drug trials
Pathos AI Raises $237 Million at $3 Billion Valuation
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
OpenAI acquires Orchestra Bio to bring AI agents into drug development
Daily AI Brief: the AI news that matters, in your inbox.